Publications

Search our bibliography using the filters on the right-hand side.

Displaying 1 through 5 of 5 publications.

Mannion L, Watson V, Mullassery V, Nair R, Charlton T, Northover M, Enting D, Van Hemelrijck M, Khan MS, Thurairaja R, Amery S, Chatterton K, Smith K, Hughes S. Treatment preferences of patients with muscle invasive bladder cancer: a discrete choice experiment. BJUI Compass. 2024 Oct 11;5(11):1059-68. doi: 10.1002/bco2.443

Pineda E, Salud A, Vila-Navarro E, Safont MJ, Llorente B, Aparicio J, Vera R, Escudero P, Casado E, Bosch C, Bohn U, Perez-Carrion R, Carmona A, Ayuso JR, Ripolles T, Bouzas R, Gironella M, Garcia-Albeniz X, Feliu J, Maurel J. Dynamic soluble changes in sVEGFR1, HGF, and VEGF promote chemotherapy and bevacizumab resistance: A prospective translational study in the BECOX (GEMCAD 09-01) trial. Tumour Biol. 2017 Jun;39(6). doi: 10.1177/1010428317705509

Herring WL, Herrmann JW. The single-day surgery scheduling problem: sequential decision-making and threshold-based heuristics. OR spectrum: quantitative approaches in management. 2012 Apr 1;34(2):429-59.

Garcia-Albeniz X, Pericay C, Alonso-Espinaco V, Alonso V, Escudero P, Fernandez- Martos C, Gallego R, Gascon P, Castellvi-Bel S, Maurel J. Serum matrilysin correlates with poor survival independently of KRAS and BRAF status in refractory advanced colorectal cancer patients treated with irinotecan plus cetuximab. Tumour Biol. 2011 Apr;32(2):417-24. doi: 10.1007/s13277-010-0136-3

Domingo-Domenech J, Castel T, Auge JM, Garcia-Albeniz XA, Conill C, Puig S, Vilella R, Matas J, Malvehy J, Gascon P, Mellado B, Molina R. Prognostic implications of protein S-100beta serum levels in the clinical outcome of high-risk melanoma patients. Tumour Biol. 2007;28(5):264-82.